Geode Capital Management
PTHS icon

Geode Capital Management’s Pelthos Therapeutics PTHS Stock Holding History

Geode Capital Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$348K Buy
16,575
+1,925
+13% +$49K ﹤0.01% 3695
2026
Q2 		$414K Sell
14,650
-640
-4% -$16.4K ﹤0.01% 3675
2026
Q1 		$321K Buy
15,290
+1,665
+12% +$39.5K ﹤0.01% 3749
2025
Q4 		$422K Buy
13,625
+3,295
+32% +$95K ﹤0.01% 3653
2025
Q3 		$289K Buy
10,330
+9,286
+889% +$225K ﹤0.01% 3809
2025
Q2 		$14.1K Buy
1,044
+37
+4% +$447 ﹤0.01% 4402
2025
Q1 		$14.3K Buy
+1,007
New +$17.2K ﹤0.01% 4406

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Geode Capital Management's PTHS Position: Q3 2026 in Review

Geode Capital Management increased its Pelthos Therapeutics (PTHS) stake by 13% in Q3 2026, buying an estimated $49K and bringing the position to 16,575 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

Geode Capital Management first reported a position in PTHS in Q1 2025 and has held it in 7 quarters since. The position peaked at $422K in Q4 2025. 5 funds tracked by Wall St. Rank hold PTHS as of Q3 2026.

  • Geode Capital Management held 16,575 shares of Pelthos Therapeutics worth $348K as of Q3 2026.
  • Geode Capital Management bought 1,925 Pelthos Therapeutics shares in Q3 2026, an estimated $49K.
  • Pelthos Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3695 holding.
  • Geode Capital Management first reported a position in Pelthos Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Geode Capital Management's Pelthos Therapeutics position peaked at $422K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.